Well Lead Medical Co (603309) Fair Value & Analysis
Healthcare · CN · Market cap 3.4B CNY
Fair value as of: Jun 24, 2026
Analysis
Well Lead Medical Co (603309) currently trades at ¥11.40, while our model-based Fair Value estimate is ¥11.87 — implying the stock looks roughly 4.1% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Well Lead Medical Co., Ltd. engages in the development, production, and sale of medical devices in urology, endourology, anaesthesia, respiratory, hemodialysis, and pain management areas worldwide. It provides urology products, including Foley catheter, Nelaton catheters, urine collection products, and accessories; endourology products, such as the ClearPetra family system, ureterorenoscope, guide wires, ureteral stent, urethral and ureteral dilation, and stone retrieval basket; anesthesia products, comprising endotracheal tubes, intubation accessories, laryngeal masks, endobronchial and tracheostomy tubes, anesthesia breathing circuits and accessories, and nasopharyngeal and oropharyngeal airway products. The company also offers respiratory products, including oxygen and aerosol therapy products, and capnography mask and cannula products; drainage/suction/gastroenterology products, such as drainage systems, Yankauer handles, suction catheters, and stomach and feeding tubes; hemodia…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Well Lead Medical Co (603309) undervalued?
What is the fair value of 603309?
What is the quality score of 603309?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.